Authors
Latest:
Ibrutnib in Older Patients With Mantle Cell LymphomaBrad S. Kahl, MD, professor in the department of medicine at Washington School of Medicine at Siteman Cancer Center, discusses the use of ibrutinib (Imbruvica) in older patients with mantle cell lymphoma. This agent is currently being investigated in the frontline setting for patients not eligible for stem cell transplant.
Latest:
KEYNOTE-826: Knowledge Gained for Cervivcal Cancer TreatmentBradley J. Monk, MD, FACS, FACOG, explains the implications of the phase 3 KEYNOTE-826 clinical trial.
Latest:
Behind KEYNOTE-826 in Persistent, Recurrent, or Metastatic Cervical CancerBradley J. Monk, MD, FACS, FACOG, discusses the rationale behind the KEYNOTE-826 study.
Latest:
Monk on KEYNOTE-A18 Data of Pembro/Chemoradiotherapy in Cervical CancerBradley J. Monk, MD, FACS, FACOG, discusses the phase 3 KEYNOTE-A18 study of pembrolizumab with chemoradiotherapy for the treatment of patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.
Latest:
McGregor Highlights Excitement and Future Directions Across GU CancersBradley McGregor, MD, discusses how ongoing trials hold the key for further breakthroughs in genitourinary cancer treatment.
Latest:
OUTBACK Trial Reveals No Benefit for Adjuvant Chemotherapy in Cervical CancerBradley Monk, MD, FACCOG, FACS, discusses the creation and findings of the OUTBACK trial.
Latest:
Improving Community Oncology Practices Through the American Oncology NetworkThe American Oncology Network is helping community oncology practices to flourish. As CEO, Bradley Prechtl, MBA, was instrumental in the organizations formation in 2017 when the need for improvement in community oncology across the United States had become evident.
Latest:
Ibrutinib Maintenance Appears Safe in MCL Following Induction TherapyIbrutinib as a maintenance therapy for patients with mantle cell lymphoma who respond to frontline induction therapy with or without autologous stem cell transplant appeared safe and feasible, according to the results of a recent study presented at the 2019 ASCO Annual Meeting.
Latest:
Identification of EGFR Mutations Impacts Overall Prognosis in Lung CancersBrennan J. Decker, MD, PhD, discusses the role of identifying <em>EGFR</em> mutations in patients with lung cancers. In lung adenocarcinoma, there are many different activating mutations that can lead to the development of cancer, Decker explains.
Latest:
Understanding Molecular Subtypes of SarcomaBrian A. Van Tine, MD, PhD, assistant professor of Medicine, Division of Oncology, Section of Medical Oncology, Washington University School of Medicine, discusses the importance of understanding molecular subtypes of sarcoma.
Latest:
Challenges With Targeted Therapies in Ovarian CancerBrian Burgess, DO, PhD, a first-year fellow at the University of Kentucky, discusses the biggest challenge with targeted therapies in ovarian cancer. PARP resistance has become a huge barrier in this treatment paradigm.
Latest:
Revlimid Plus Dexamethasone Versus Standard Treatment for Multiple MyelomaBrian G.M. Durie, MD, chairman, International Myeloma Foundation (IMF), hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses results from a phase III trial that compared lenalidomide (Revlimid) plus dexamethasone versus the standard treatment of melphalan plus prednisone and thalidomide (MPT) in patients with multiple myeloma who are over 65 years old. Durie offers his thoughts regarding the impact of this trial.
Latest:
Prevention of Cytomegalovirus After Allogeneic HSCTTwo poster presentations at the 2018 BMT Tandem Meetings of the Center for International Blood & Marrow Transplant Research and the American Society for Blood and Marrow Transplantation, provided a compelling extension of the recent phase III clinical trial that demonstrated the efficacy of prophylactic therapy with letermovir (Prevymis) for the prevention of cytomeg alovirus (CMV) infection in patients receiving allogeneic hematopoietic stem cell transplantation (HSCT).
Latest:
First-Line Treatment for Advanced Clear Cell RCC: Key TakeawaysClosing out their discussion on advanced RCC, expert hematologist/oncologists offer key takeaways from their discussion and look toward future treatment evolution in the first-line setting.
Latest:
Results of the SWOG S0500 TrialBrian Leyland-Jones, MBBS, PhD, director of Edith Sanford Breast Cancer Research, discusses the results of the SWOG S0500 trial, which looked at circulating tumor cell (CTC) levels in patients with metastatic breast cancer.
Latest:
Dr. Brian Nussenbaum on the Difficulties of Improving Survival in Larynx CancerNussenbaum says the current balance in the treatment paradigm of larynx cancer is between surreal and cure, all while maintaining a functional preservation for the patient.
Latest:
Unmet Needs and Future Outlook in aRCC TreatmentThe panel explores unmet needs in aRCC treatment and shares expectations for changes and advances in the landscape in the near future.
Latest:
Evolving Role of CAR T-Cell Therapy in Mantle Cell LymphomaBrian Hill, MD, discusses the use of CAR T-cell therapy in earlier lines of treatment for mantle cell lymphoma and identifies other novel agents in this setting.
Latest:
Dr. Van Tine Discusses the Development of Olaratumab in SarcomaBrian Van Tine, MD, PhD, assistant professor, Washington University School of Medicine, discusses the development of olaratumab (Lartruvo) in soft tissue sarcoma.
Latest:
Results of a Phase II Study of LHRH Therapy in High-Risk Prostate CancerBridget F. Koontz, MD, associate professor of radiation oncology, Duke Cancer Institute, discusses a single-arm, phase II trial of 6 months of concurrent androgen deprivation therapy/abiraterone acetate (Zytiga) plus prednisone and definitive radiotherapy for men with intermediate- to high-risk localized prostate cancer.
Latest:
Genomic Profiling Provides Much-Needed Prognostic Data in GliomaResults from a genomic and molecular analysis presented at the 2015 ASCO Annual Meeting and published in Acta Neuropathology indicate that low-grade gliomas may be classified into three distinct prognostic categories based on genomic data.
Latest:
Genomic Profiling Improves Outcomes in Metastatic CancersTargeted therapy, as determined by genomic profiling, outperformed standard of care in patients with pretreated metastatic cancers.
Latest:
Expert Discusses Long-Term Efficacy of Pembrolizumab in MelanomaEric Whitman, MD, discusses data for pembrolizumab in the frontline treatment of advanced melanoma and ongoing research with the agent in other settings of the disease.
Latest:
Novel Treatment Strategies Are Explored in Pancreatic CancerOutcomes in pancreatic cancer may be improving for the first time in decades. With pancreatic cancer projected to be the second leading cause of cancer-related deaths in the United States by the year 2030,1 this projection brings welcome optimism to the field.
Latest:
Early Activity With Frontline Sacituzumab Govitecan/Pembro in Metastatic NSCLCIn patients with metastatic non–small cell lung cancer given sacituzumab govitecan-hziy with pembrolizumab, positive response rates were observed.
Latest:
Using the LGR5 Protein as a Biomarker in Thyroid CancerBrittany N. Bohinc, MD, Division of Endocrinology, Duke University, discusses the potential to use LGR5 as a biomarker in papillary thyroid cancer.
Latest:
Dr. O'Neil Discusses Robotic Prostatectomy Versus Open SurgeryBrock O'Neil, MD, physician instructor in urologic surgery, Vanderbilt University, discusses robotic prostatectomy versus open surgery.
Latest:
The Mechanism of Action and Use of Antibody Drug ConjugatesBruce D. Cheson, MD, Professor of Medicine, Head of Hematology, Director of Hematology Research, Georgetown Lombardi Comprehensive Cancer Center, describes the mechanism of action of antibody drug conjugates and their use.
